Recently, the State Drug Administration approved Jiangsu Hengrui Medicine Co.Ltd(600276) the listing of class 1 innovative drug darcilil hydroxyethanesulfonate tablets (trade name: arikang) through the priority review and approval procedure. The drug combined with fluticasone is suitable for patients with recurrent or metastatic breast cancer with hormone receptor positive and human epidermal growth factor receptor 2 negative after previous endocrine therapy.
Dalpiciclib is a cyclin dependent kinase 4 and 6 (CDK4 and Cdk6) inhibitor, which can reduce the phosphorylation level of retinoblastoma protein downstream of CDK4 and Cdk6 signaling pathway and induce G1 phase arrest, so as to inhibit the proliferation of tumor cells. The listing of the drug provides a new treatment option for breast cancer patients.
(website of the State Drug Administration)
